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A 29-year-old woman presented with secondary amenorrhea, 
primary infertility, and virilization, which had developed over 
the past 2 years was suspected to have a virilizing tumor at 
her left ovary. Her serum testosterone level was markedly 
elevated (380 ng/dL). Left salpingooophorectomy was performed, 
and histopathological examination revealed a thecoma of the 
left ovary. The postoperative serum testosterone level returned 
to 65 ng/dL. The patient did not have regression of virilism 
soon. However, the patient had a normal menstruation 29 days 
after surgery and gave birth to a baby 13 months after surgery. 
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INTRODUCTION
Virilizing ovarian tumors are a rare cause of 
hyperandrogenism in women, and account for 
less than 5% of all ovarian neoplasms and those 
that are malignant for less than 10% of all ovarian 
cancers.
1-4  In most cases the hormonal abnormalities 
present in patients with virilizing ovarian tumors 
include increased serum testosterone levels in the 
presence of normal levels of serum dehydroepian-
drosterone-sulfate.
5 Most hormonally active ovarian 
tumors belong to the gonadal stroma category.
3 
Ovarian thecoma is a rare benign tumor of stro-
mal cell origin, and represents less than 1% of all 
ovarian tumors. It occurs most often in perimeno-
pausal and postmenopausal women.
6 Typical the-
comas are almost always estrogenic; the luteinized 
forms are virilizing in about 10% of cases.
2 We 
report the case of a 29-year-old woman with a left 
ovarian virilizing thecoma who gave birth to a 
baby 13 months after surgery. 
CASE REPORT
A 29-year-old woman (gravida 0, para 0) who 
had complained of secondary amenorrhea, primary 
infertility, and progressive virilization; hirsutism, 
deepening voice, acne, enlargement of the clitoris 
admitted to our hospital in July 2004 with the 
suspicion of a virilizing ovary tumor. The virilizing 
manifestations were progressive from June 2003. 
She had no special past medical history and family 
history. She had regular menstruation of 28 days 
cycle starting at 14, however the menstruation 
ceased in December 2002. She had never been 
pregnant in 18 months of her married life.
Physical examination showed hirsutism of her 
face and body, a deep voice, acne on her face, and 
enlargement of the clitoris. However, she had no 
features suspected Cushing syndrome. Breasts 
and muscles were normal but left adnexal mass 
about 5 cm was palpated on gynecological exami-
nation. Her blood pressure was 120/80 mmHg. 
Hemoglobin, hematocrit, fasting blood glucose, 
serum electrolytes, cholesterol, triglyceride, calcium, 
phosphorus, and renal and liver function tests 
were normal. Tumor marker levels in the serum 
of CA 125, CA 19 - 9, and AFP were normal. Her 
chest X-ray and EKG detected no abnormalities. 
Endocrine evaluation revealed a markedly in-
creased serum testosterone concentration (380 ng/ 
dL), while the concentrations of dehydroepiandro-
sterone-sulfate was within normal range (180 μg/ 
dL). Serum prolactin and thyroid stimulating 
hormone (TSH) were normal. Serum luteinizing Mun-Hwi Lee, et al. 170
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Fig. 1. Transvaginal ultrasonography of a homogenous- 
echoic mass originated in the left ovary (A), and abdomi-
nal and pelvic computed tomography (CT) scans of a left 
ovarian solid mass which was well-demarcated, round, 
homogenous and well-enhanced. No pathologic findings 
of other pelvic organs, ascites, and lymphatic enlarge-
ments were detected (B). 
Fig. 2. A smooth-surfaced, yellowish, solid, and movable 
tumor was found to originate in the left ovary, measured 
7×5c m .
hormone (LH; 14.7 mIU/mL), follicle stimulating 
hormone (FSH; 2.0 mIU/mL), and estradiol (55.0 
pg/mL) concentrations were within normal range.
Transvaginal ultrasound examination suggested 
the presence of a solid, movable, and homogenous- 
echoic mass (6.3 × 4.1 cm) originated in the left 
ovary. No pathologic findings within right ovary 
and uterus were found. No ascites was detected. 
Abdominal and pelvic computed tomography 
(CT) scans demonstrated a left ovarian solid mass 
measuring 5.5 cm in diameter. The mass was well- 
demarcated, round, homogenous and well-en-
hanced. No pathologic findings of other pelvic 
organs, ascites, and lymphatic enlargements were 
detected (Fig. 1).
At laparotomy, a smooth-surfaced, yellowish, 
solid, and movable tumor was found to originate 
in the left ovary, and measured 7 × 5 cm (Fig. 2). 
The uterus and right ovary were macroscopically 
normal. No pelvic adhesion, ascites, and findings 
of dissemination from the malignant ovarian tumor 
were observed in the abdominal cavity. So we 
performed left salpingooophorectomy.
Histopathological examination of the left ovarian 
tumor revealed a thecoma consisting of spindle 
cells with blunt ended nuclei and ill defined cyto-
plasm. The solid mass was consisted of fascicles 
of stromal cells, and some were vacuolated (Fig. 
3). Masson trichrome staining shows very little 
collagen deposition in focal stromal pattern sup-
posed to be a fibroma component (Fig. 4). There 
were no other tumor components such as granulosa 
c e l l  t u m o r ,  o r  f i b r o s a r c o m a  i n  t h i s  t u m o r .
The postoperative course was uncomplicated. 
She was discharged from hospital without any 
complications on the 4th day after surgery. Four-
teen days after the surgery, serum testosterone 
level was reduced to 65 ng/dL. She had a normal 
menstruation 29 days after the surgery, and after 
that menstruation she was pregnant. On 10 June 
2005 (38 weeks and 5 days of gestation), she gave 
birth to a male baby, 3,560 gm in weight and Apgar 
score 8/9 by cesarean section due to breech pre-
sentation. On 29 September 2006, she gave birth 
to the second baby boy, 3,020 gm in weight (Apgar 
score 8/9) by cesarean section.
A
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Fig. 4. Masson trichrome staining shows very little collagen deposition in focal stromal pattern (arrow) ((A) × 100, (B) × 400).
Fig. 3. A thecoma consisting of spindle cells with blunt ended nuclei and ill defined cytoplasm. The solid mass was 
consisted of fascicles of stromal cells, and some were vacuolated (H & E, (A) × 100, (B) × 400).
DISCUSSION
Ovarian thecoma, which is classified as a ger-
minal cord interstitial ovarian tumor, is very rare, 
accounting for about 1% of solid ovarian tumors.
4 
The incidence of this tumor is reported to be 
highest among pre- and postmenopausal women 
of 50 - 60 years of age.
7 Most thecomas range 
within 5 - 10 cm in size and are bilateral in 3% of 
cases.
8 It is generally agreed that thecomas are 
benign although most of them are solid. Non- 
malignant disorders usually follow a more slowly 
progressive benign course, as compared with the 
rapid progressive virilization seen with underlying 
malignancy.
9 It has been suggested that a simple 
clinical assessment and a single serum testosterone 
measurement may be sufficient to differentiate 
between benign and malignant virilizing tumors 
in women presenting with hirsutism and andro-
genetic features.
10 The value o measuring serum 
androstenedione levels has been shown to be of 
less benefit. A full endocrinological evaluation is 
usually indicated in the patients with an elevated 
serum testosterone level.
Ovarian stromal cell tumors may secret large 
amounts of testosterone, which may produce ra-
pidly progressing androgenic effects.
11 Theca cell 
tumors may secret also cause hyperandrogenism, 
12  although these tumors usually appear to be estro-
genic.
1 Androgen secretion of an ovarian tumor 
before menarche results in heterosexual precocity, 
with virilizing manifestation and accelerated 
AB
A BMun-Hwi Lee, et al. 172
Yonsei Med J Vol. 50, No. 1, 2009
somatic growth.
13 During reproductive age the 
typical picture of androgen secretion is oligome-
norrhea, defeminization and progressive masculi-
nization (hirsutism, temporal balding, enlarge-
ment of the clitoris, deepening of the voice and 
muscular development).
4 In the case of a 24-year- 
old woman described by Takeuchi and collea-
gues,
14 masculinization developed over a few 
months. Symptoms of defeminization and mas-
culinization may appear simultaneously but signs 
of defeminization usually show before those of 
masculinization.
15 
A post-menopausal woman occasionally has a 
history of long-standing mild virilism. The patients 
with ovarian thecoma and concomitant post-meno-
pausal bleeding, endometrial hyperplasia, endo-
metrial carcinoma were reported in post-meno-
pausal women.
16 Our patient presented virilizing 
features developed over 13 months, progressive 
from June 2003. 
Surgery is the primary treatment of virilizing 
thecoma. Wedge resection of ovarian lesions suffices 
for patients who need to preserve fertility, but 
oophorectomy is performed more commonly 
because patients sometimes have thecoma mixed 
with granulose cell tumor which has low malig-
nant potential. Hysterectomy can be performed on 
patients who don't need to keep their uterus because 
patients with thecoma may have endometrial 
hyperplasia or endometrial carcinoma.
17 
After surgery, symptoms of defeminization may 
disappear. Four months after the surgery, mens-
truation begins and other symptoms disappear in 
the order of their appearance but enlargement of 
clitoris may last for 20 years.
18 This patient began 
her menstruation 29 days after the surgery. The 
prognosis of our patient was good and we have 
not observed relapse during follow-up. 
In our case, we also performed left salpingooo-
phorectomy. Fourteen days after the surgery, 
serum testosterone level was reduced to normal 
range. She had a normal menstruation 4 weeks 
after the surgery, and after that menstruation she 
was pregnant. Also, she gave birth to a baby boy 
without any complications. Ovarian virilizing tu-
mors are an uncommon cause of common clinical 
problems. Our patient was treated by unilateral 
oophorectomy, a curative therapy for ovarian 
thecoma, which resulted in a favorable obstetric 
outcome.
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